Download PDF
Thromb Haemost 1997; 78(01): 117-120
DOI: 10.1055/s-0038-1657512
Venous thromboembolism and cancer, a two-way clinical association
Schattauer GmbH Stuttgart

Venous Thromboembolism and Gancer: a Two-Way Clinical Association

Giancarlo Agnelli
Istituto di Medicina Interna e Medicina Vascolare, Università di Perugia, Perugia, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
21 August 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Trousseau A. Phlegmasia alba dolens. Lectures on clinical medicine, delivered at the Hotel-Dieu de Paris. London, New Sydenham Society: 1872: 281-295
    Google Scholar
  • 2 Donati MB, Poggi A. Malignancy and haemostasis. Br J Haematol 1980; 44: 173-182
    CrossrefPubMedGoogle Scholar
  • 3 Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990; 17: 147-159
    PubMedGoogle Scholar
  • 4 Rickies FR, Levine MN, Edwards RI. Hemostatic alterations in cancer patients. Cancer Metast Rev 1992; 11: 237-248
    CrossrefPubMedGoogle Scholar
  • 5 Falanga A, Barbui T, Rickies FR, Levine MN. Guidelines for clotting studies in cancer patients. Thromb Haemost. 1993; 70: 540-542
    PubMedGoogle Scholar
  • 6 Kakkar AK, De RuvoN, Chinswangwatanakul V, Tebbutt S, Williamson RCN. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995; 346: 1004-1005
    CrossrefPubMedGoogle Scholar
  • 7 Sproul EE. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938; 34: 566-585
    PubMedGoogle Scholar
  • 8 Gore JM, Appelbaum JS, Greene HL, Dexter L, Dalen JE. Occult cancer in patients with acute pulmonary embolism. Ann IntMed 1982; 96: 556-560
    CrossrefPubMedGoogle Scholar
  • 9 Aderka D, Brown A, Zelikovski A, Pinkhas J. Idiopathic deep vein thrombosis in an apparenty healthy patient as a premonitory sign of occult cancer. Cancer 1986; 57: 1846-1849
    CrossrefPubMedGoogle Scholar
  • 10 Griffin MR, Stanson AW, Brown ML, Hauser MF, O’Fallon WM, Anderson HM, Kazmier FJ, Melton III LJ. Deep venous thrombosis and pulmonary embolism. Arch Intern Med 1987; 147: 1907-1911
    CrossrefPubMedGoogle Scholar
  • 11 Goldberg RJ, Seneff M, Gore JM, Anderson FA, Greene HL, Wheeler HB, Dalen JE. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med 1987; 147: 251-253
    CrossrefPubMedGoogle Scholar
  • 12 Monreal M, Lafoz E, Casals A, Inaraja L, Montserrat E, Ma CallejasJ, Martorell A. Occult cancer in patients with deep venous thrombosis: a systematic approach. Cancer 1991; 67: 541-545
    CrossrefPubMedGoogle Scholar
  • 13 Prandoni P, Lensing AWA, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, Ten CateJW. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. New Engl J Med 1992; 327: 1128-1133
    CrossrefPubMedGoogle Scholar
  • 14 Monreal M, Casals A, Boix J, Olazabal A, Montserrat E, Mundo MR. Occult cancer in patients with acute pulmonary embolism. Chest 1993; 103: 816-819
    CrossrefPubMedGoogle Scholar
  • 15 Nordstrom M, Lindblad B, Anderson H, Bergqvist D, Kjellström T. Deep venous thrombosis and occult malignancy: an epidemiological study. Br Med J 1994; 308: 891-894
    CrossrefPubMedGoogle Scholar
  • 16 Naschitz JE, Yeshurun D, Eldar S, Lev LM. Diagnosis of cancer-associated vascular disorders. Cancer 1996; 77: 1759-1767
    CrossrefPubMedGoogle Scholar
  • 17 Bastounis EA, Karayiannakis AJ, Maiiri Gg, Alexiou D, Papalambros L. The incidence of occult cancer in patients with deep venous thrombosis: a prospective study. J Int Med 1996; 239: 153-156
    CrossrefPubMedGoogle Scholar
  • 18 Cornuz J, Pearson SD, Creager M, Cook EF, Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 1996; 125: 785-793
    CrossrefPubMedGoogle Scholar
  • 19 Prins MH, Lensing AWA, Hirsh J. Idiopathic deep venous thrombosis. Is a search for malignant disease justified?. Arch Intern Med 1994; 154: 1310-1315
    CrossrefPubMedGoogle Scholar
  • 20 Clagett JP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Ann Surg 1988; 208: 227-240
    CrossrefPubMedGoogle Scholar
  • 21 Shen VS, Poliak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?. South Med J 1980; 73: 841-843
    CrossrefPubMedGoogle Scholar
  • 22 Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep vein thrombosis after major gynecological surgery using labelled fibrinogen-phlebography and lung scanning. J Obstet Gynaecol Br Commonw 1974; 08: 311-316
    PubMedGoogle Scholar
  • 23 Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg 1992; 127: 310-313
    CrossrefPubMedGoogle Scholar
  • 24 Falanga A, Ofosu FA, Cortellazzo S, Delaini F, Consonni R, Caccia R, Longatti S, Maran D, Rodeghiero F, Pogliani E, Marassi A, D’Angelo A, Barbui T. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993; 85: 745-750
    CrossrefPubMedGoogle Scholar
  • 25 Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995; 108: 312-334
    CrossrefPubMedGoogle Scholar
  • 26 Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, Buck nall, Stevens J, Port eous. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease?. A double-blind, randomised, multicenter comparison. Thromb Haemost 1993; 70: 562-567
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Godwin J. Use of low molecular weight heparins in malignancy-related thromboembolic disorders: a clinical review. Clin Appl Thromb/Hemost 1996; 02: 28-34
    PubMedGoogle Scholar
  • 28 Danis J, Bergqvist D. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2,500 versus 5,000 anti Xa units in 2070 patients. Br J Surg 1995; 82: 1283-1284
    CrossrefPubMedGoogle Scholar
  • 29 Bergqvist D. Low molecular weight heparin (enoxaparin) as thromboprophylaxis in cancer surgery. Haemostasis 1996; 26 S (03) 01
    PubMedGoogle Scholar
  • 30 Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De pauwS. The thrombogenic effect of anti-cancer drug therapy in women with stage II breast cancer. New Engl J Med 1988; 318: 404-407
    CrossrefPubMedGoogle Scholar
  • 31 Saphner T, Tomey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 09: 286-294
    CrossrefPubMedGoogle Scholar
  • 32 Goodnough LT, Saito H, Manni A, Jones PH, pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen: a study of 159 patients. Cancer 1984; 54: 1264-1268
    CrossrefPubMedGoogle Scholar
  • 33 Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard K, Stewart D, Goodwin P. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-889
    CrossrefPubMedGoogle Scholar
  • 34 Lokich JJ, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 1983; 52: 1586-1589
    CrossrefPubMedGoogle Scholar
  • 35 Bern MM, Bothe Jr A, Bistrian B, Champagne CD, Keane MS, Blackburn GL. Prophylaxis against central vein thrombosis with low-dose warfarin. Surgery 1986; 99: 216-221
    PubMedGoogle Scholar
  • 36 Bern MM, Lokich JJ, Wallach SR, Bothe A, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Ann Intern Med 1990; 112: 423-428
    CrossrefPubMedGoogle Scholar
  • 37 Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices. Prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251-253
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Zacharski LR, henderson WG, rorman WB. et al Bleeding complications from warfarin anticoagulation in patients with malignancy. J Med 1985; 16: 535-561
    PubMedGoogle Scholar
  • 39 Chahinian AP, Ware JH, Zim mer. Update on anticoagulation carcinoma of the lung (SCCL). Proc Am Clin Oncol 1985; 04: 191
    PubMedGoogle Scholar
  • 40 Prandoni P, Lesing AWA, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten CateJW. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-445
    CrossrefPubMedGoogle Scholar
  • 41 Hull RD, Raskob GL, Pineo GF. et al Subcutaneous low-molecular-weight heparin compared with intravenous heparin in the treatment of proximal-vein thrombosis. New Eng J Med 1992; 326: 975-982
    CrossrefPubMedGoogle Scholar
  • 42 Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992; 339: 1476
    PubMedGoogle Scholar